• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCOVID-19 vaccines

Why I took China’s Sinopharm vaccine, despite its lack of data

Grady McGregor
By
Grady McGregor
Grady McGregor
Down Arrow Button Icon
Grady McGregor
By
Grady McGregor
Grady McGregor
Down Arrow Button Icon
February 5, 2021, 8:00 PM ET

Our mission to make business better is fueled by readers like you. To enjoy unlimited access to our journalism, subscribe today.

China’s COVID-19 vaccine development process has been relatively opaque.

Unlike their Western counterparts, Chinese vaccine makers Sinopharm and Sinovac have not published Phase III trial data in peer-reviewed medical journals or released much information about their vaccines beyond press releases and headline efficacy figures, even as Beijing touts the vaccines as a source of national pride and uses them as a means of diplomacy. Sinopharm says its vaccine is 79% effective in preventing COVID-19 infections. Sinovac has not released its own efficacy data, but partners in Turkey, Indonesia, and Brazil have reported efficacy rates ranging from 50% to 91%.

But Chinese vaccine makers still have been successful in marketing their drugs. Sinovac and Sinopharm have gained approval in over a dozen countries and have begun distributing hundreds of millions of COVID-19 doses around the world.

Early Phase I and II data suggest the Chinese vaccines are safe, but without peer-reviewed analysis from later-stage testing, millions of people who’ve been offered the vaccines must rely on scant information as they wrestle with questions about the vaccine’s efficacy, its potential side effects, and how the jabs work across different age groups.

Will Henry, a 31-year-old American teacher in Shanghai, got an email through his school in late December asking if he wanted to get Sinopharm’s vaccine. Henry, who spoke with Fortune for a story about Chinese vaccine makers’ data, said he was hesitant at first, given the lack of transparency in Chinese vaccines. But ultimately he chose to take it to improve the chances that he could safely travel home to the U.S. and see his family. Below, in a conversation edited for length and clarity, Henry tells Fortune about his decision.

Fortune: You got your first jab of the Sinopharm vaccine in Shanghai in early January and your second later that month. Can you describe the experience of receiving the first dose?

Henry: I was looking forward to it, and it seemed like one of the most important vaccines I will get in my life. We took a bus to a repurposed sports complex that had been changed to a vaccine center. When I went, it was really packed. I could tell there were more people there than the organizers had planned for.

https://twitter.com/helloitswill44/status/1348202108101619712

I waited in line for about an hour and a half. They then checked my QR code on my phone. Within 10 minutes I had a needle in my arm. (Editor’s note: In the pandemic, China has employed QR codes on health code apps to track individuals’ COVID risk.)

Later I got an email from my health clinic mentioning a paper receipt we were given. If I didn’t have it, [the email said] the school nurse could just check my QR code and print it off for me. 

How did you feel after getting the vaccine?

I had no side effects. I was almost looking forward to having one because I heard that’s a sign that it’s working, but I’m going to take having no side effects as a good thing.

My life hasn’t really changed at all either, but I’m feeling more optimistic. I don’t know if that’s because I got vaccinated or that I’m looking at numbers in the U.S. and seeing more and more people getting vaccinated.  

How did you weigh the pros and cons of getting the Sinopharm vaccine?

It was a pretty easy decision for me, because I’m stuck here right now. I could leave and go back to the U.S. but I’d be risking my social life and job here. But I want to go see my parents, so anything that could make that easier, you know, I would jump at that opportunity. (Editor’s note: For much of 2020, China barred the entry of all foreign nationals, including visa holders. But since last September, China has allowed foreigners to reenter the country after undergoing mandatory two-week hotel quarantines.)

The decision did pit two parts of me against one another. I am very pro-vaccination, but at the same time I was a little bit hesitant about the lack of transparency in China. But I think the fact that a foreign country had approved the Sinopharm vaccine gave me more confidence in it.

Did your colleagues also take it? 

It was a big conversation in the office. What surprised me was that a lot more expat staff percentage-wise were willing to take it than Chinese staff.

I asked [Chinese staff] why, and they’d just tell me it’s not safe yet, or they’re not sure, or it came out too quickly. But I guess for them, they don’t have to leave China, it’s pretty safe here. It’s not a risk they need to take. 

When you go to the U.S., do you think it will matter you got vaccinated in China?

When I go home, I have wondered if [my Chinese vaccine shot] will be accepted in the U.S. Will there be some things I can’t take part in? Or will I need something saying I got vaccinated in the U.S.?

But [based on case numbers], I’d certainly rather be living in China with a vaccine shot that’s 80% effective than in the U.S. with a vaccine shot that’s 90% effective.

About the Author
Grady McGregor
By Grady McGregor
LinkedIn iconTwitter icon
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

PoliticsModerna
FDA backtracks and agrees to review Moderna mRNA flu vaccine after initial rejection
By Lauran Neergaard and The Associated PressFebruary 18, 2026
2 hours ago
Healthsleep
The 4 Best Bed Frames of 2026: Expert Tested
By Christina SnyderFebruary 18, 2026
5 hours ago
Successthe future of work
As boomer and Gen X bosses retire, working from home will make a major comeback, new research predicts—and you have work-life balance loving Gen Z to thank
By Orianna Rosa RoyleFebruary 17, 2026
1 day ago
HealthHealth
Confronting Asia’s growing rate of chronic conditions means tackling cultural issues as much as medical ones
By Stuart A. SpencerFebruary 15, 2026
3 days ago
Susan Blumenthal
AICancer
Meet the American spies who helped mammograms save more lives
By Erik GermanFebruary 15, 2026
3 days ago
HealthDietary Supplements
5 Best Nootropics of 2026: Expert Reviewed Supplements
By Christina SnyderFebruary 13, 2026
5 days ago

Most Popular

placeholder alt text
AI
Thousands of CEOs just admitted AI had no impact on employment or productivity—and it has economists resurrecting a paradox from 40 years ago
By Sasha RogelbergFebruary 17, 2026
1 day ago
placeholder alt text
Personal Finance
You need $2 million to retire and 'almost no one is close,' BlackRock CEO warns, a problem that Gen X will make 'harder and nastier'
By Sydney LakeFebruary 17, 2026
1 day ago
placeholder alt text
Economy
Trump crackdown drives 80% plunge in immigrant employment, reshaping labor market, Goldman says
By Nick LichtenbergFebruary 17, 2026
1 day ago
placeholder alt text
Economy
$56 trillion national debt leading to a spiraling crisis: Budget watchdog warns the U.S. is walking a crumbling path
By Nick LichtenbergFebruary 17, 2026
1 day ago
placeholder alt text
Personal Finance
Current price of silver as of Tuesday, February 17, 2026
By Joseph HostetlerFebruary 17, 2026
1 day ago
placeholder alt text
Commentary
Something big is happening in AI — and most people will be blindsided
By Matt ShumerFebruary 11, 2026
7 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.